세계의 BCG 결핵 백신 시장 규모 : 유형별, 용도별, 최종사용자별, 지역별 범위 및 예측

Global BCG Tuberculosis (TB) Vaccine Market Size By Type (Immune, Therapy), By Application (Pediatrics, Adults), By End-User (Hospitals, Clinics) By Geographic Scope And Forecast

US $ 3,950 ￦ 5,411,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 6,644,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,344,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

BCG 결핵 백신 시장 규모 및 전망

BCG 결핵(TB) 백신 시장 규모는 2024년에는 5,349만 달러로 2026년부터 2032년까지 3.90%의 CAGR로 성장할 것으로 예상되며, 2032년에는 7,264만 달러에 달할 것으로 예상됩니다.

• BCG(Bacillus Calmette-Guerin) 백신은 주로 결핵 치료에 사용됩니다. 결핵을 일으키는 결핵균과 유사한 미생물인 마이코박테리움 보비스의 약독성 균주입니다.
• 이 백신은 특히 결핵에 걸릴 위험이 높은 영아에게 출산 직후에 접종되며, BCG 백신은 면역학적 반응을 자극하여 치명적인 유형의 결핵으로부터 영아를 보호합니다. 또한 방광암 치료에도 사용됩니다.

세계 BCG 결핵 백신 시장 역학

BCG 결핵 백신 시장을 형성하는 주요 시장 역학은 다음과 같습니다.

주요 시장 촉진요인

• 높은 결핵 발병률 : 전 세계적으로 높은 결핵 발병률이 지속되고 있는 것은 BCG 백신 접종 사업의 주요 촉진요인입니다. 세계보건기구(WHO)의 '세계 결핵 보고서 2023'에 따르면, 2022년 결핵에 걸린 사람은 1,060만 명으로 추정되며, 그 중 130만 명은 어린이입니다. 이 분석에 따르면, 결핵은 여전히 세계 최악의 전염병 중 하나이며, 2022년에는 130만 명이 결핵으로 사망할 것으로 예상됩니다. 이러한 큰 질병 부담은 효과적인 결핵 예방 활동, 특히 BCG 백신 접종의 지속적인 필요성을 강조하고 있습니다.
• 결핵 퇴치를 위한 정부의 노력과 자금 지원 증가 : 결핵 퇴치를 위한 정부의 지원과 자금 조달 증가는 BCG 백신 시장을 촉진하고 있으며, Stop TB Partnership에 따르면 2022년 전 세계 결핵 자금 조달액은 58억 달러에 달해 지금까지 보고된 것 중 가장 높은 수준을 기록했습니다. 그러나 이는 '세계 결핵 퇴치 계획 2018-2022'가 제시한 2022년까지 필요한 연간 지출액 130억 달러에 미치지 못합니다. 결핵 퇴치에 대한 관심이 높아짐에 따라 예방접종에 대한 지출이 강화될 것으로 예상됩니다.
• 신흥국에서의 인식 제고 및 예방접종 프로그램 확대 : 특히 결핵 발병률이 높은 신흥국에서의 예방접종 프로그램 확대가 BCG 백신에 대한 수요를 증가시키고 있습니다. 유니세프에 따르면 전 세계 BCG 백신 접종률은 2000년 85%에서 2019년 88%로 증가했습니다. 결핵이 유행하는 동남아시아에서는 2019년 BCG 접종률이 95%에 달했습니다. 이러한 고부담 지역에서의 접종률 확대 추세는 앞으로도 지속될 것으로 예상되며, 이에 따라 시장의 성장이 예상됩니다.

주요 과제

• BCG 백신 사용에 따른 부작용 : BCG 백신은 림프절 부종, 고열, 주사 부위 피부 감염 등의 부작용이 있습니다. 드물지만, 이러한 부작용은 백신 접종 수용과 시장 성장을 저해하는 요인으로 작용하고 있습니다. 부작용에 대한 면밀한 모니터링과 관리가 필수적입니다.
• BCG 백신의 효과에 대한 우려 : BCG 백신은 새롭게 출현한 결핵균에 대한 예방 효과에 의문이 제기되고 있습니다. 이러한 신종 균주에 대한 예방접종이 효과가 없다면 수요가 감소하고 시장 성장이 둔화될 것이며, BCG 백신의 효능을 유지하기 위해서는 지속적인 연구와 개선이 필요합니다.
• 공급 부족 : BCG 백신의 부족은 시장 확대를 제한합니다. 공급망 문제, 제조상의 문제 또는 생산 부족으로 인해 공급 부족이 발생하여 특히 결핵 발병률이 높은 국가에서는 백신의 접근성이 제한됩니다. 전 세계 수요를 충족하고 결핵을 줄이기 위해서는 충분하고 안정적인 공급이 필요합니다.

주요 동향:

• 높은 결핵 발병률로 인한 세계 수요 증가 : 결핵의 세계적 확산은 특히 저개발 국가에서 여전히 공중보건에 큰 위협이 되고 있습니다. 세계보건기구(WHO)는 매년 수백만 명이 결핵에 새로 감염될 것으로 예상하고 있으며, 이는 BCG 백신에 대한 수요를 촉진하고 있습니다. 각국 정부는 결핵 예방의 중요성을 인식하고 예방접종 캠페인을 시작하고 의료 시설에 대한 투자를 진행하고 있습니다.
• 소아 예방접종 프로그램에 대한 관심 : 소아기 예방접종 프로그램은 특히 결핵 유병률이 높은 지역에서 점점 더 중요해지고 있습니다. 정부와 보건기관은 결핵성 수막염과 같은 심각한 결핵을 예방하기 위해 신생아 예방접종을 우선순위에 두고 있습니다. 이러한 추세는 결핵 예방에 대한 인식 제고에 초점을 맞춘 국제적인 프로그램과 캠페인에 의해 강화되어 BCG 백신에 대한 수요가 증가하고 있습니다.
• 새로운 백신 후보의 출현 : 재조합 BCG 백신, 서브유닛 백신 등 새로운 개량형 결핵 백신이 현재 개발 중입니다. 이들 후보물질은 기존 BCG 백신의 한계를 극복하고 다양한 결핵균주에 대한 효능을 향상시키기 위해 노력하고 있습니다. 이러한 새로운 백신의 출시는 시장 환경을 변화시키고, 임상시험과 규제 당국의 승인이 진행됨에 따라 향후 성장을 촉진할 것으로 예상됩니다.

목차

제1장 BCG 결핵(TB) 백신 세계 시장 소개

• 시장의 도입
• 조사 범위
• 가정

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH 조사 방법

• 데이터 마이닝
• 검증
• 1차 자료
• 데이터 소스 리스트

제4장 BCG 결핵 백신 세계 시장 전망

• 개요
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• Porter's Five Forces 모델
• 밸류체인 분석

제5장 BCG 결핵 백신 세계 시장 : 유형별

• 개요
• 면역 BCG
• 치료 BCG

제6장 BCG 결핵 백신 세계 시장 : 용도별

• 개요
• 소아
• 성인

제7장 BCG 결핵 백신 세계 시장 : 최종사용자별

• 개요
• 병원
• 진료소

제8장 BCG 결핵 백신 세계 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 세계 기타 지역
  • 라틴아메리카
  • 중동

제9장 세계의 결핵 백신 시장 경쟁 구도

• 개요
• 각사의 시장 순위
• 주요 개발 전략

제10장 기업 개요

• Merck
• Sanofi Pasteur
• Japan BCG Lab
• China National Biotec
• Serum Institute of India
• Intervax
• GSBPL

제11장 부록

• 관련 조사

ksm

영문 목차

영문목차

BCG Tuberculosis (TB) Vaccine Market Size and Forecast

BCG Tuberculosis (TB) Vaccine Market size was valued at USD 53.49 Million in 2024 and is projected to reach USD 72.64 Million by 2032, growing at a CAGR of 3.90% from 2026-2032.

• The BCG (Bacillus Calmette-Guerin) vaccine is primarily used to treat tuberculosis. It is a weakened strain of Mycobacterium bovis, a microbe similar to M. tuberculosis that causes tuberculosis.
• The vaccine is provided shortly after delivery, particularly to infants at high risk of tuberculosis. The BCG vaccine stimulates an immunological response, protecting babies and young children from deadly types of tuberculosis. It is also used to treat bladder cancer.

Global BCG Tuberculosis (TB) Vaccine Market Dynamics

The key market dynamics that are shaping the BCG Tuberculosis (TB) vaccine market include:

Key Market Drivers

• High Global Tuberculosis Burden: The persistently high worldwide tuberculosis load is a major driver of the BCG vaccination business. According to the World Health Organization's Global Tuberculosis Report 2023, an estimated 10.6 million individuals became ill with tuberculosis in 2022, including 1.3 million children. According to the analysis, tuberculosis remains one of the world's worst infectious diseases, accounting for 1.3 million fatalities in 2022. This significant disease burden highlights the ongoing need for effective tuberculosis prevention efforts, particularly BCG vaccination.
• Increasing Government Initiatives and Funding: Growing government support and financing for tuberculosis control initiatives is propelling the BCG vaccine market. According to the Stop TB Partnership, global TB financing reached $5.8 billion in 2022, the highest level reported to date. However, this falls short of the $13 billion yearly expenditure required by 2022, as indicated by the Global Plan to End Tuberculosis 2018-2022. The increased emphasis on tuberculosis elimination is anticipated to enhance expenditure on vaccination efforts.
• Rising Awareness and Expanding Immunization Programs in Developing Countries: Expanding immunization programs, particularly in developing countries with high tuberculosis burdens, are driving up demand for BCG vaccines. According to UNICEF, global BCG vaccine coverage has increased from 85% in 2000 to 88% in 2019. In South-East Asia, where tuberculosis is endemic, BCG coverage reached 95% in 2019. This trend of expanding coverage in high-burden areas is projected to continue, resulting in market growth.

Key Challenges:

• Side Effects Associated with the Use of BCG Vaccine: The BCG vaccine has side effects such as swollen lymph nodes, high fever, and skin infections at the injection site. Despite their rarity, these side effects hinder vaccination acceptance and market growth. Careful monitoring and control of any adverse effects is essential.
• Concerns Regarding the Efficacy of BCG Vaccines: There are questions regarding the BCG vaccine's effectiveness to protect against new tuberculosis strains that have appeared. If the vaccination is ineffective against these new strains, it diminishes demand and slows market growth. Ongoing research and improvement are required to ensure that the BCG vaccine stays effective.
• Shortage of Supply: A lack of BCG vaccines limits market expansion. Supply chain problems, manufacturing challenges, or underproduction cause shortages and restrict the availability of the vaccine, particularly in high-burden nations. Meeting global demand and reducing tuberculosis require an adequate and stable supply.

Key Trends:

• Increasing Global Demand Due to High TB Prevalence: The global prevalence of tuberculosis remains a major public health concern, particularly in underdeveloped nations. The World Health Organization (WHO) predicts millions of new tuberculosis infections each year, fueling demand for the BCG vaccine. As governments acknowledge the importance of combating tuberculosis, they are launching vaccination campaigns and investing in healthcare facilities, which are projected to considerably enhance market growth in the future years.
• Focus on Childhood Immunization Programs: Childhood immunization programs are becoming increasingly important, particularly in areas with high tuberculosis prevalence. Governments and health organizations are prioritizing neonatal vaccination to prevent serious types of tuberculosis, such as TB meningitis. This focus is reinforced by international programs and campaigns focused on raising awareness about tuberculosis prevention, which drives higher demand for the BCG vaccine.
• Emergence of Novel Vaccine Candidates: New and improved tuberculosis vaccines, such as recombinant BCG vaccines and subunit vaccinations, are now under development. These candidates seek to overcome the limitations of the current BCG vaccine and improve its efficacy against various tuberculosis strains. The prospective launch of these novel vaccines is projected to disrupt the market environment and drive future growth as they go through clinical trials and regulatory approval.

Global BCG Tuberculosis (TB) Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the BCG Tuberculosis (TB) vaccine market:

Asia Pacific:

• According to Verified Market Research, the Asia Pacific region is estimated to dominate over the forecast period. The Asia Pacific area has a disproportionately high tuberculosis load, fueling up demand for BCG vaccines. According to the World Health Organization's Global Tuberculosis Report 2023, six of the eight countries responsible for two-thirds of global tuberculosis cases in 2022 were in Asia Pacific: India (27%), Indonesia (9.2%), China (7.4%), the Philippines (7%), Pakistan (5.7%), and Bangladesh (3.6%). This high disease load demands ongoing and extended immunization efforts in the region.
• BCG immunization is primarily targeted at the Asia Pacific region's huge and rising pediatric population. According to the United Nations Population Division, Asia is home to about half of the world's children, with a projected 1.2 billion under the age of 18 in 2020. According to UNICEF, India, which has the region's highest pediatric population, there were roughly 27 million births in 2022. The region's BCG vaccine demand is driven by its large and expanding pediatric population.
• Furthermore, many Asia Pacific countries are currently working to improve their healthcare infrastructure and increase immunization coverage. For example, according to WHO and UNICEF estimates of national vaccination coverage, BCG vaccine coverage in Southeast Asia increased from 87% in 2000 to 95% by 2022. Since 2000, BCG coverage in the Western Pacific region, which includes China and other East Asian countries, has generally been higher than 95%. This trend of upgrading healthcare systems and extending vaccination programs is a major driver of the BCG vaccine market in the region.

North America:

• North America is estimated to exhibit significant growth during the forecast period. North America, particularly the United States, sees a lot of immigration from countries with high tuberculosis rates, which drives up the demand for BCG immunization. According to the Centers for Disease Control and Prevention (CDC), 8,300 tuberculosis (TB) infections were reported in the United States in 2022. The CDC also states that foreign-born individuals account for the bulk of tuberculosis cases in the United States, with an incidence rate 14 times higher than that of U.S.-born people in 2022. This demographic pattern highlights the importance of BCG immunization in the region.
• Furthermore, the BCG vaccine is being utilized as an immunotherapy for bladder cancer, which is generating demand in North America. According to the American Cancer Society, approximately 82,290 new cases of bladder cancer (62,460 in men and 19,830 in women) are expected to be detected in the United States by 2023. The association also believes that bladder cancer is the fourth most frequent malignancy in men. The increasing prevalence of bladder cancer in North America has increased the need for the BCG vaccine as a therapy option.

Europe:

• Europe region is estimated to exhibit substantial growth during the forecast period. Europe has seen a considerable influx of immigrants from countries with high tuberculosis prevalence, pushing up demand for BCG vaccine. According to the European Centre for Disease Prevention and Control (ECDC), foreign-born people accounted for 29.4% of TB infections in the EU/EEA in 2019. Foreign-born cases ranged from 0% to 95.7% in reporting nations. This demographic transition has led to a greater emphasis on tuberculosis prevention techniques, such as BCG vaccination for high-risk groups.
• Furthermore, TB vaccine research and development in Europe is on the rise, with enhanced BCG formulations among the highlights. Between 2003 and 2020, the European & Developing Countries Clinical Trials Partnership (EDCTP) contributed more than €157 million in 52 grants for clinical research on tuberculosis vaccines. This investment comprises around 15% of EDCTP's total portfolio. The increased R&D focus is likely to stimulate innovation in the BCG vaccine industry and potentially broaden its applications.

BCG Tuberculosis (TB) Vaccine Market: Segmentation Analysis

The BCG Tuberculosis (TB) Vaccine Market is segmented based on Type, Application, End-User, and Geography.

BCG Tuberculosis (TB) Vaccine Market, By Type

• Immune BCG
• Therapy BCG

Based on Type, the market is segmented into Immune BCG and Therapy BCG. The immune BCG segment is estimated to dominate the BCG Tuberculosis (TB) vaccine market due to immune BCG's success in preventing tuberculosis, which has led to widespread acceptance and incorporation into national immunization programs around the world. The lack of alternative vaccinations for immune BCG has further strengthened its standing, as healthcare providers continue to rely on it for tuberculosis prevention.

BCG Tuberculosis (TB) Vaccine Market, By Application

• Pediatrics
• Adults

Based on Application, the market is segmented into Pediatrics and Adults. The pediatrics segment is estimated to dominate the BCG Tuberculosis (TB) vaccine market. BCG vaccination is primarily administered to infants and young children because it gives up to 80% protection against severe types of pediatric tuberculosis, such as TB meningitis. Children have a higher risk of contracting tuberculosis than adults. Continuous government measures for tuberculosis immunization in children are helping to drive the segment's growth.

BCG Tuberculosis (TB) Vaccine Market, By End-User

• Hospitals
• Clinics

Based on End-User, the BCG Tuberculosis (TB) vaccine market is divided into Hospitals and Clinics. According to VMR analyst, the hospital segment is estimated to dominate the market over the forecast period due to hospitals' extensive healthcare services, which include immunization programs for babies and at-risk groups. Hospitals are frequently equipped with the required infrastructure and skilled personnel to properly deliver the BCG vaccine, making them an ideal location for TB preventive initiatives. Furthermore, hospitals play an important role in handling tuberculosis patients, which helps to secure their market position.

BCG Tuberculosis (TB) Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the BCG Tuberculosis (TB) vaccine market is classified into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific region is expected to dominate the market during the forecasted period. This domination is mostly due to the high incidence of tuberculosis in countries such as India and China, which account for a sizable proportion of worldwide TB cases. Government attempts to increase vaccine coverage, as well as raising knowledge about tuberculosis prevention, contribute to the region's strong market position. As a result, Asia Pacific is projected to continue to drive the BCG vaccination market.

Key Players

• The "BCG Tuberculosis (TB) Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, Serum Institute of India, Intervax, and GSBPL.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• BCG Tuberculosis (TB) Vaccine Market Recent Developments
• In July 2021, The New Jersey-based Hackensack Meridian Center for Discovery and Innovation (CDI) announced that it had received USD 6.4 million in funding from the National Institutes of Health to investigate a novel idea for a tuberculosis vaccine. The CDI team has suggested that BCG would be enhanced by designing it to promote B-cell proliferation and survival.
• In March 2022, The Serum Institute of India Pvt. Ltd. requested the Drugs Controller General of India, seeking the emergency usage of authorization for its recombinant BCG vaccination to combat tuberculosis. Throughout the projected period, the BCG vaccine market will benefit from the approval of this vaccine.
• In January 2023, The WHO intended to establish a new "TB Vaccine Accelerator Council". The committee will speed up the formation of a high-level coalition comprising international organizations, donors, end users, and governments to identify and address obstacles to the development of tuberculosis vaccines like BCG. It will also help authorize and implement innovative TB vaccines

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY TYPE

• 5.1 Overview
• 5.2 Immune BCG
• 5.3 Therapy BCG

6 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Pediatrics
• 6.3 Adults

7 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Clinics

8 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East

9 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Merck
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Sanofi Pasteur
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Japan BCG Lab
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 China National Biotec
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Serum Institute of India
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Intervax
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 GSBPL
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments

11 Appendix

• 11.1 Related Research

관련자료